Skip to main content
. 2017 Jul-Sep;9(3):94–102.

Table 2.

Oligonucleotide primers used in this study.

Primer Nucleotide sequence 5’-3’ Application
E150–5Sal (for) TTTTGTCGACCCTGTACCTTATTCT Amplification of enhancer E and introduc-
tion of SalI and BglII restriction sites
E150–5Bgl2 (rev) TTTAGATCTATCCTTGCCTTAAGGC
rs3753381-F ATTTTTACAGAGTTCACAGCTTCCAGA rs3753381(A) design
rs3753381-R CTGTGAACTCTGTAAAAATGTTTACTTGGA
S1enh7F AGAAGAATTTGGGGGCAGAGAGGACT Amplification of enhancer D and intro
duction of SalI restriction site
S1enh7SalR (rev) AAAAGTCGACCCGCCCTTTTTCATGAGTTAAAC
for G RXRA TACGGATTTATCAGCTTCCAGAAAA mut RXR G design
rev G RXRA AAGCTGATAAATCCGTAAAAATGT TTAC
for A RXRA TACAGATTTATCAGCTTCCAGAAAA mut RXR A design
rev A RXRA AGCTGATAAATCTGTAAAAATGT TTAC
for G FOXO3 CATTACAACGGAGTTCACAGCTT mut FOX G design
rev G FOXO3 CTCCGTTGTAATGTTTACTTGGATG
for A FOXO3 CATTACAACAGAGTTCACAGCTT mut FOX A design
rev A FOXO3 CTCTGTTGTAATGTTTACTTGGATG